Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 nM.
|Solubility (25°C)||DMSO 70 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Robert H Howland. Trifluoperazine: A Sprightly Old Drug
 Magdolna Tardy, et al. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia
 Kai Koch, et al. Trifluoperazine versus placebo for schizophrenia
 L O Marques, et al. Trifluoperazine for schizophrenia
 R MACDONALD, et al. Trifluoperazine dihydrochloride (stelazine) in paranoid schizophrenia
|Related Dopamine Receptor Products|
TAK-906 is a peripherally restricted, non-BBB permeable molecule that targets the posterior region of the stomach and vomiting center for the study of gastric cramps.
LY3154885 is an orally active dopamine D1 receptor orthosteric modulator (PAM).
ONC206 is a selective antagonist of dopamine D2-like receptor (DRD2) and has broad-spectrum anti-tumor activity.
Trifluoperazine is an FDA-approved antipsychotic drug for schizophrenia. It is an inhibitor of calmodulin (CaM) and Dopamine D2 receptor with an IC50 value of 1.2 nM for D2 receptor.
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain and is used to treat a variety of neurological and psychiatric disorders.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.